The future of medicine is in the microbiome

Siolta’s live microbial therapeutics are designed from naturally occurring bacteria in order to reestablish a
healthy microbiome with the power to prevent and reduce disease.

Siolta Therapeutics has leveraged human infant gut microbiome and clinical data to understand early-life microbial networks that promote healthy gut microbiome development. Our science focuses on decoding these interactions and identifying the specific microbes that promote appropriate gut microbiome development in early life to prevent immune dysfunction and promote healthy development in childhood. As a result, our unique platform allows us to develop and test novel microbiome-based therapeutics to treat and prevent disease.

The human body harbors a complex ecosystem of interconnected microbial life forms collectively referred to as the Human Microbiome. This ecosystem develops rapidly in early life, and the genetic information it encodes confers functional properties important for human health. In humans, the largest accumulation of microbes resides in the gut, where they interact with an array of human immune cells. Siolta’s science focuses on decoding these interactions and identifying the specific microbes that promote appropriate gut microbiome development in early life to prevent immune dysfunction and promote healthy development in childhood.

We use the developing gut microbiome of infants to understand how the microbiome promotes healthy immune development.